CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT WITH COMBINATION OF CORTICOSTEROIDS AND LONG-ACTING SS-2-AGONIST

PATHOS CLINICAL STUDY RESULTS

Abstract

Chronic obstructive pulmonary disease (COPD) is a chronic, continually progressive lung disease, significantly worsening patients’ quality of life. The longer COPD duration, moderate and severe disease forms are asocciated with more frequent disease exacerbations, which significantly disrupts patient's clinical condition and disease course. To avoid this, it is needed adequate treatment, which can effectively reduce the number of exacerbation and help to maintain sufficient lung function. Currently is a wide choice of medication for the treatment of COPD, but commonly prescribed for moderate and severe COPD are Fluticasonum / Salmeterolum and Budesonidum / Formoterolum. The one aim of the PATHOS study was to evaluate the effectiveness and security of these combinations.